Home/Biosimilar Atlas/Ranibizumab/Reliance Life Sciences ranibizumab

Reliance Life Sciences ranibizumab

Ranibizumab biosimilar developed by Reliance Life Sciences. Reference product Lucentis.

Brands by market: Brand not published by CDSCO (India) · Commercial partner or holder: Reliance Life Sciences · Company profile
FDANot listed
EMANot listed
MHRANot listed
PMDANot listed
HCNot listed
CDSCOMar 2020permitted
EDENot listed
Approved or registered in 1 of 7 markets
Connections
RanibizumabmoleculeReliance Life Sciencesdeveloper1 of 7markets0trials behind it13other products, same developer5rival developers in its markets

About Reliance Life Sciences ranibizumab

Reliance Life Sciences received its ranibizumab permission in India in March 2020 for wet macular degeneration, with the diabetic and vein occlusion uses added in 2024. It offers two strengths.

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union

Not listed by EMA.

MHRA

United Kingdom

Not listed by MHRA.

PMDA

Japan

Not listed by PMDA.

HC

Canada

Not listed by HC.

CDSCO

India

Central Drugs Standard Control OrganisationApproved
Brand
Not published by CDSCO (INN only)
Holder or applicant
Reliance Life Sciences Pvt Ltd
Pathway
Similar Biologic, manufacture and marketing permission
Approved
Mar 2020
Application or permission
MF/BIO/20/000024; drug substance MF/BIO/20/000026; additional indications MF/BIO/24/000077
Indications as licensed
Wet AMD at permission; RVO, DME, diabetic retinopathy added July 2024
Presentations
2.3 mg/0.23 mL and 1.38 mg/0.23 mL vials
Source
S011 (CDSCO) · checked Sep 2026
EDE

United Arab Emirates

Not listed by EDE.

Other developers in the same markets

Where Reliance Life Sciences ranibizumab holds an approval, these are the other ranibizumab biosimilars approved in that market.

MarketRivalsDevelopers (product)
CDSCO5Enzene Biosciences (Enzene Biosciences ranibizumab), Intas Pharmaceuticals (Rexatilux / Razumab), Lupin (Ranluspec / Vislyfa), Sun Pharmaceutical Industries (Sun Pharma ranibizumab), Zenotech Laboratories (Zenotech ranibizumab)

Same developer, other molecules

Other biosimilars in the Atlas developed by Reliance Life Sciences: Reliance Life Sciences adalimumab, Reliance Life Sciences bevacizumab, Reliance Life Sciences darbepoetin alfa, Reliance Life Sciences denosumab, Reliance Life Sciences etanercept, Reliance Life Sciences follitropin alfa, Reliance Life Sciences golimumab, Reliance Life Sciences infliximab, Reliance Life Sciences omalizumab, Reliance Life Sciences rituximab, Reliance Life Sciences somatropin, Reliance Life Sciences trastuzumab, UstekiRel.

Chronology

Sources

All ranibizumab biosimilars

Planning ranibizumab biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.